Taeko Minegishi1,2,3, Melissa M Garrido4,5, Michael Stein5, Elizabeth M Oliva6,7, Austin B Frakt4,5,8. 1. Partnered Evidence-based Policy Resource Center, VA Boston Healthcare System, MA, Boston, USA. taeko.minegishi@va.gov. 2. Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA. taeko.minegishi@va.gov. 3. Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. taeko.minegishi@va.gov. 4. Partnered Evidence-based Policy Resource Center, VA Boston Healthcare System, MA, Boston, USA. 5. Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA. 6. VA Office of Mental Health and Suicide Prevention, VA Program Evaluation and Resource Center, VA Palo Alto Healthcare System, Menlo Park, CA, USA. 7. VA Center for Innovation to Implementation, VA Palo Alto Healthcare System, Menlo Park, CA, USA. 8. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Cambridge, MA, USA.
Abstract
BACKGROUND: Prior opioid discontinuation studies have focused on one of two characteristics of opioid prescribing, its duration (long term vs not) or dosage (high vs low). Questions remain about the experience of patients with high-dose, long-term opioid therapy (HLOT) prescriptions who are likely to be at the highest risk for adverse events. OBJECTIVE: We address the following questions among the Veterans Health Administration (VHA) patients receiving HLOT: 1), How has the prevalence of discontinuation of opioids changed over time? 2), How do patient characteristics vary between those who do and do not discontinue? And 3), how does the prevalence of discontinuation vary geographically? DESIGN: A retrospective observational study of VHA patients with HLOT between fiscal year (FY) 2014 and FY2018. PARTICIPANTS: We identified 1,281,330 patients from VHA outpatient opioid prescription data with at least a 1-day opioid supply between FY2014 and FY2018. We identified and excluded those receiving palliative care or diagnosed with metastatic cancer. MAIN MEASURES: For a given patient and month, a patient having a 3-month moving average of ≥ 90 daily morphine milligram equivalent (MME) was defined as having HLOT. Similarly, we used a three-month average MME of zero as discontinuation. KEY RESULTS: The prevalence of discontinuation among patients with HLOT increased from 6.3% in FY2014 to 7.8% in FY2018. Across the years, patients who discontinued were younger, less likely to be married, and more likely to have comorbidities related to substance use disorders compared with patients who continued to receive HLOT. Incidence of discontinuation among those with HLOT increased in more than half (64%) of the 129 VHA medical centers. CONCLUSION: Prevalence of patients receiving HLOT in the VHA decreased as the incidence of discontinuation increased. Further research is needed to understand the process by which patients are discontinued and to assess the relationship between discontinuation and health outcomes.
BACKGROUND: Prior opioid discontinuation studies have focused on one of two characteristics of opioid prescribing, its duration (long term vs not) or dosage (high vs low). Questions remain about the experience of patients with high-dose, long-term opioid therapy (HLOT) prescriptions who are likely to be at the highest risk for adverse events. OBJECTIVE: We address the following questions among the Veterans Health Administration (VHA) patients receiving HLOT: 1), How has the prevalence of discontinuation of opioids changed over time? 2), How do patient characteristics vary between those who do and do not discontinue? And 3), how does the prevalence of discontinuation vary geographically? DESIGN: A retrospective observational study of VHA patients with HLOT between fiscal year (FY) 2014 and FY2018. PARTICIPANTS: We identified 1,281,330 patients from VHA outpatient opioid prescription data with at least a 1-day opioid supply between FY2014 and FY2018. We identified and excluded those receiving palliative care or diagnosed with metastatic cancer. MAIN MEASURES: For a given patient and month, a patient having a 3-month moving average of ≥ 90 daily morphine milligram equivalent (MME) was defined as having HLOT. Similarly, we used a three-month average MME of zero as discontinuation. KEY RESULTS: The prevalence of discontinuation among patients with HLOT increased from 6.3% in FY2014 to 7.8% in FY2018. Across the years, patients who discontinued were younger, less likely to be married, and more likely to have comorbidities related to substance use disorders compared with patients who continued to receive HLOT. Incidence of discontinuation among those with HLOT increased in more than half (64%) of the 129 VHA medical centers. CONCLUSION: Prevalence of patients receiving HLOT in the VHA decreased as the incidence of discontinuation increased. Further research is needed to understand the process by which patients are discontinued and to assess the relationship between discontinuation and health outcomes.
Authors: Mark J Edlund; Bradley C Martin; Andrea Devries; Ming-Yu Fan; Jennifer Brennan Braden; Mark D Sullivan Journal: Clin J Pain Date: 2010-01 Impact factor: 3.442
Authors: Philip W Chui; Lori A Bastian; Eric DeRycke; Cynthia A Brandt; William C Becker; Joseph L Goulet Journal: Health Serv Res Date: 2018-10-08 Impact factor: 3.402
Authors: Kurt Kroenke; Daniel P Alford; Charles Argoff; Bernard Canlas; Edward Covington; Joseph W Frank; Karl J Haake; Steven Hanling; W Michael Hooten; Stefan G Kertesz; Richard L Kravitz; Erin E Krebs; Steven P Stanos; Mark Sullivan Journal: Pain Med Date: 2019-04-01 Impact factor: 3.750
Authors: Lyna Z Schieber; Gery P Guy; Puja Seth; Randall Young; Christine L Mattson; Christina A Mikosz; Richard A Schieber Journal: JAMA Netw Open Date: 2019-03-01
Authors: Sterling McPherson; Crystal Lederhos Smith; Steven K Dobscha; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Travis I Lovejoy Journal: Pain Date: 2018-10 Impact factor: 7.926
Authors: Ingrid A Binswanger; Susan M Shetterly; Stanley Xu; Komal J Narwaney; David L McClure; Deborah J Rinehart; Anh P Nguyen; Jason M Glanz Journal: JAMA Netw Open Date: 2022-10-03
Authors: Luana Colloca; Ariana Taj; Rachel Massalee; Nathaniel R Haycock; Robert Scott Murray; Yang Wang; Eric McDaniel; Thomas M Scalea; Yvette Fouche-Weber; Sarah Murthi Journal: Front Psychiatry Date: 2022-07-04 Impact factor: 5.435